Circio Holding ASA

OB:CRNA Stock Report

Market Cap: NOK 30.6m

Circio Holding Future Growth

Future criteria checks 5/6

Circio Holding is forecast to grow earnings and revenue by 61.2% and 110.5% per annum respectively while EPS is expected to decline by 140.2% per annum.

Key information

61.2%

Earnings growth rate

-140.2%

EPS growth rate

Biotechs earnings growth12.2%
Revenue growth rate110.5%
Future return on equityn/a
Analyst coverage

Low

Last updated15 Nov 2024

Recent future growth updates

Recent updates

Circio Holding ASA's (OB:CRNA) CEO Will Probably Struggle To See A Pay Rise This Year

May 29
Circio Holding ASA's (OB:CRNA) CEO Will Probably Struggle To See A Pay Rise This Year

Targovax ASA's (OB:TRVX) Intrinsic Value Is Potentially 96% Above Its Share Price

Aug 24
Targovax ASA's (OB:TRVX) Intrinsic Value Is Potentially 96% Above Its Share Price

Health Check: How Prudently Does Targovax (OB:TRVX) Use Debt?

Jul 08
Health Check: How Prudently Does Targovax (OB:TRVX) Use Debt?

Is Targovax (OB:TRVX) Using Debt In A Risky Way?

Oct 27
Is Targovax (OB:TRVX) Using Debt In A Risky Way?

Is Targovax (OB:TRVX) A Risky Investment?

Jul 05
Is Targovax (OB:TRVX) A Risky Investment?

Shareholders May Be A Bit More Conservative With Targovax ASA's (OB:TRVX) CEO Compensation For Now

Mar 10
Shareholders May Be A Bit More Conservative With Targovax ASA's (OB:TRVX) CEO Compensation For Now

Is Targovax (OB:TRVX) Using Debt In A Risky Way?

Feb 20
Is Targovax (OB:TRVX) Using Debt In A Risky Way?

The Chief Scientific Officer of Targovax ASA (OB:TRVX), Victor Levitsky, Just Bought A Few More Shares

Dec 05
The Chief Scientific Officer of Targovax ASA (OB:TRVX), Victor Levitsky, Just Bought A Few More Shares

Earnings and Revenue Growth Forecasts

OB:CRNA - Analysts future estimates and past financials data (NOK Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202614481N/A811
12/31/202561-418-42
12/31/2024N/A1817182
6/30/202409-49-49N/A
3/31/20240-51-69-69N/A
12/31/20230-111-89-89N/A
9/30/202310-446-103-98N/A
6/30/202310-449-115-110N/A
3/31/202310-440-112-107N/A
12/31/202210-433-114-109N/A
9/30/2022N/A-107-105-105N/A
6/30/2022N/A-110-94-94N/A
3/31/2022N/A-106-91-91N/A
12/31/2021N/A-98-85-85N/A
9/30/2021N/A-98-87-87N/A
6/30/20210-97-94-94N/A
3/31/20210-105-100-100N/A
12/31/20201-108-111-111N/A
9/30/20203-117-122-122N/A
6/30/20203-120-128-128N/A
3/31/20203-132-134-134N/A
12/31/20192-148-143-143N/A
9/30/20190-153-135-135N/A
6/30/20190-162-132-132N/A
3/31/20190-153-125-125N/A
12/31/20180-147-112-112N/A
9/30/20180-139-111-111N/A
6/30/20180-132-108-108N/A
3/31/20180-129N/A-112N/A
12/31/20170-122N/A-107N/A
9/30/20170-121N/A-106N/A
6/30/20170-119N/A-102N/A
3/31/20170-118N/A-104N/A
12/31/20160-122N/A-109N/A
9/30/20160-134N/A-120N/A
6/30/20160-137N/A-129N/A
3/31/20160-117N/A-105N/A
12/31/20150-92N/A-81N/A
9/30/20150-57N/A-54N/A
6/30/20150-32N/A-28N/A
3/31/20150-22N/A-18N/A
12/31/20140-18N/A-14N/A
9/30/2014-3-12N/A-8N/A
6/30/2014-1-10N/A-7N/A
3/31/20140-9N/A-9N/A
12/31/20130-8N/A-8N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: CRNA's forecast earnings growth (61.2% per year) is above the savings rate (2.4%).

Earnings vs Market: CRNA's earnings (61.2% per year) are forecast to grow faster than the Norwegian market (9.3% per year).

High Growth Earnings: CRNA's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: CRNA's revenue (110.5% per year) is forecast to grow faster than the Norwegian market (2.2% per year).

High Growth Revenue: CRNA's revenue (110.5% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if CRNA's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y